Sicras Antoni, Rejas Javier, Navarro Ruth, Serrat Josep, Blanca Milagrosa
Badalona Serveis Assistencials, Badalona, Barcelona, Spain.
Bipolar Disord. 2008 Jul;10(5):607-16. doi: 10.1111/j.1399-5618.2008.00599.x.
To estimate the prevalence of metabolic syndrome (MS) in patients with bipolar disorder (BD) included in a Health Management Organization (HMO) database.
A cross-sectional analysis of the administrative claim database of Badalona Serveis Assistencials (BSA) was performed. All patients of either sex over 16 years of age and receiving treatment for BD for more than three weeks were included in the study group. The reference group comprised the rest of patients in the BSA database without BD. MS was defined according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III modified criteria and required fulfillment of at least three of the following five components: body mass index (BMI) >or=28.8 kg/m(2), triglycerides >or=150 mg/dL, high-density lipoprotein (HDL) cholesterol <40 mg/dL (males)/<50 mg/dL (females), blood pressure >or=130/85 mmHg, and fasting glucose >or=110 mg/dL. Descriptive statistics, bivariate analysis, and logistic regression models were applied.
We identified 178 patients with BD out of 86,028 subjects (50.5% women; 45.5 +/- 17.8 years, mean +/- SD) included in the BSA database. MS prevalence was significantly higher in BD: 24.7% [95% confidence interval (CI): 18.6-31.7] versus 14.4% (CI: 14.2-14.7) with no statistically significant differences between genders; age-adjusted odds ratio (OR) = 1.65 (1.11-2.44, p = 0.013). All MS components were higher in the BD group, particularly BMI >28.8 kg/m(2) [33.1% (26.3-40.6) versus 17.9% (17.7-18.2), adjusted OR = 2.05 (1.46-2.87, p < 0.001)], high triglyceride levels [23.0% (17.1-29.9) versus 11.3% (11.1-11.5), adjusted OR = 2.09 (1.45-3.02, p < 0.001)], and low HDL cholesterol levels [54.5% (46.9-62.0) versus 29.4% (29.1-29.7), adjusted OR = 2.77 (2.02-3.80, p < 0.001)]. Furthermore, patients with BD showed a significantly higher frequency of obesity [41.4% (32.3-50.9) versus 27.1% (26.6-27.5); adjusted OR = 1.83 (1.24-2.68, p = 0.002)].
Compared with the general population managed by the BSA, the prevalence of MS was significantly higher in patients with BD, mainly due to a higher prevalence of obesity, high triglyceride levels, and low HDL cholesterol levels. These findings strongly support the development of health policies addressing this problem in BD patients.
评估健康管理组织(HMO)数据库中双相情感障碍(BD)患者代谢综合征(MS)的患病率。
对巴达洛纳辅助服务机构(BSA)的行政索赔数据库进行横断面分析。研究组纳入所有年龄超过16岁、接受BD治疗超过三周的男女患者。对照组包括BSA数据库中未患BD的其他患者。MS根据美国国家胆固醇教育计划(NCEP)成人治疗小组(ATP)III修订标准定义,要求满足以下五个组成部分中的至少三项:体重指数(BMI)≥28.8 kg/m²、甘油三酯≥150 mg/dL、高密度脂蛋白(HDL)胆固醇<40 mg/dL(男性)/<50 mg/dL(女性)、血压≥130/85 mmHg以及空腹血糖≥110 mg/dL。应用描述性统计、双变量分析和逻辑回归模型。
在BSA数据库纳入的86,028名受试者(50.5%为女性;平均年龄45.5±17.8岁,均值±标准差)中,我们识别出178例BD患者。BD患者中MS患病率显著更高:24.7%[95%置信区间(CI):18.6 - 31.7],而对照组为14.4%(CI:14.2 - 14.7),性别间无统计学显著差异;年龄调整后的优势比(OR)= 1.65(1.11 - 2.44,p = 0.013)。BD组所有MS组成部分的患病率均更高,尤其是BMI>28.8 kg/m²[33.1%(26.3 - 40.6)对17.9%(17.7 - 18.2),调整后OR = 2.05(1.46 - 2.87,p < 0.001)]、高甘油三酯水平[23.0%(17.1 - 29.9)对11.3%(11.1 - 11.5),调整后OR = 2.09(1.45 - 3.02,p < 0.001)]以及低HDL胆固醇水平[54.5%(46.9 - 62.0)对29.4%(29.1 - 29.7),调整后OR = 2.77(2.02 - 3.80,p <